Exchange Bulletin
Essa Pharma Inc. (EPI) To Trade On Toronto Stock Exchange
July 27, 2015
Essa Pharma Inc. (the “Company”) – An application has been granted for the original listing in the Industrial category of 26,515,774 common shares of the Company, of which 22,616,387 common shares are issued and outstanding, and 3,899,387 common shares are reserved for issuance.
The common shares of the Company will be listed and posted for trading at the opening on Tuesday, July 28, 2015.
The Company is subject to the reporting requirements of Section 501 of the TSX Company Manual.
| Stock Symbol: "EPI" | CUSIP: 29668H 10 4 | Trading Currency: CDN$ |
| Temporary Market Maker: | Mackie Research Capital Corp. |
| Other Markets: | The common shares of the Company have been listed on TSX Venture Exchange since January 27, 2015 under the stock symbol “EPI”. The common shares will be delisted from TSX Venture Exchange on Tuesday, July 28, 2015 upon commencement of trading on TSX. |
| Head Office Address: | 720 – 999 West Broadway Street Vancouver, BC V5Z 1K5 |
| Email Address: | info@essapharmaceuticals.com |
| Website Address: | www.essapharma.com |
| Head Office Telephone Number: | (778) 331-0962 |
| Investor Relations: | David Wood Tel: (778) 331-0962 Email: dwood@essapharmaceuticals.com |
| Chief Financial Officer: | David Wood |
| Corporate Secretary: | Dr. Raymond Andersen |
| Incorporation: | The Company was incorporated under the name “Essa Pharma Inc.” pursuant to the Business Corporations Act (British Columbia) on January 6, 2009 |
| Fiscal Year End: | September 30 |
| Nature of Business: | The Company is a development-stage pharmaceutical company focused on the development of small molecule drugs for the treatment of castrate-resistant prostate cancer. |
| Transfer Agent & Registrar: | Computershare Investor Services Inc. at its principal offices in Vancouver and Toronto. |
| Dividends: | The Company has not paid any dividends or made any distributions since incorporation. The Company does not anticipate paying dividends in the foreseeable future. |
